Icon Group - proposed joint venture with Cyberknife Australia Pty Ltd

Summary

The Icon Group (Icon) and Cyberknife Australia Pty Ltd (Cyberknife Australia) propose to enter into a joint venture to establish up to 6 new radiation oncology clinics, which will provide radiation oncology treatments using the ‘Cyberknife’ system.

Icon is a large provider of cancer care services. In Australia, Icon provides radiation oncology services, pharmaceutical compounding services, pharmacy management services and clinical cancer trials. Icon operates radiation oncology clinics in all states of Australia and the ACT.

The Cyberknife system uses linear accelerators to provide radiation oncology treatment, specifically using Stereotactic Body Radiotherapy and Stereotactic Radiosurgery techniques. Cyberknife machines are manufactured by the US company Accuray. Accuray does not have any ownership interest in Cyberknife Australia.

5D Clinics (5D) operates one of the two Cyberknife systems in Australia, which is based at 5D’s facility in Perth. The other Cyberknife system in Australia is at the Sir Charles Gairdner Hospital in Perth (a public hospital). 5D does not own or operate any other clinics in Australia.

Market inquiries

Submissions are invited from interested parties regarding Icon Group’s proposed joint venture with Cyberknife Australia by 4pm on 10 April 2024. 

Submissions should be forwarded electronically (preferably in PDF format) to mergers@accc.gov.au with the title: "Submission re: Icon Group". 

For more details, please refer to the Market Inquiries Letter published below. 

Following 10 April 2024, queries regarding the ACCC’s review may also be addressed to mergers@accc.gov.au.

For more details, please refer to the Market Inquiries letter published below.